Trial Profile
An Open-label, Phase II Basket Study of a hypoMEThylating Agent Oral Azacitidine and DURvalumab (MEDI4736) (Anti-PDL1) in Advanced Solid Tumors (METADUR)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Durvalumab (Primary)
- Indications Advanced breast cancer; Carcinoma; Colorectal cancer; HER2 negative breast cancer; Male breast cancer; Ovarian cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms METADUR
- 30 Mar 2021 Status changed from active, no longer recruiting to completed.
- 20 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Apr 2019 Results (n=28) presented at the 110th Annual Meeting of the American Association for Cancer Research